Oncternal Therapeutics Dividend
Dividend criteriumcontroles 0/6
Oncternal Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
2.2%
Terugkoop Rendement
Totaal aandeelhoudersrendement | 2.2% |
Toekomstig dividendrendement | n/a |
Dividendgroei | n/a |
Volgende betaaldatum dividend | n/a |
Ex-dividenddatum | n/a |
Dividend per aandeel | n/a |
Uitbetalingsratio | n/a |
Recente dividendupdates
Geen updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if ONCT's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if ONCT's dividend payments have been increasing.
Dividendrendement versus markt
Oncternal Therapeutics Dividendrendement versus markt |
---|
Segment | Dividendrendement |
---|---|
Bedrijf (ONCT) | n/a |
Markt onderkant 25% (US) | 1.5% |
Markt Top 25% (US) | 4.5% |
Gemiddelde industrie (Biotechs) | 2.2% |
Analist prognose (ONCT) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate ONCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate ONCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate ONCT's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as ONCT has not reported any payouts.